UNSPSC 51281618: Neomycin

This classification denotes an aminoglycoside antibiotic with the molecular formula C23H46N6O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I16QD7X297, more generally known as neomycin. European Medicines Agency schedules neomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03406MIG. The term NEOMYCIN is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 32, no 10 1978, list 18.

UNSPSC 51281618 Neomycin, a Commodity code, nominally covers a specific antibiotic pharmaceutical; however, recent state and local solicitations tagged with this code show little activity directly aligned with neomycin procurement. The most recent opportunities are concentrated in broader pharmacy and pharmaceutical supply categories — generic multi-source drug contracting, naloxone and drug deactivation systems, and emergency medical consumables — rather than neomycin as a line item. State and local buyers using this code include state health and human services departments, county health authorities, cities (fire and rescue divisions), and cooperative purchasing alliances. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, and the Texas Health and Human Services Commission are among the active issuing bodies. Work solicited includes standing-term contracts for generic pharmaceuticals distributed through authorized wholesalers, direct-to-manufacturer prescription fulfillment programs, emergency medical supply acquisitions with quarterly or as-needed delivery, and pharmaceutical benefit management arrangements. Buyers require vendors to meet cGMP and Drug Supply Chain Security Act (DSCSA) compliance, maintain specified insurance, provide National Drug Codes and product traceability data, and often deliver within tight windows (five working days for emergency supplies, quarterly for standing programs).

Recent solicitations span Florida, Texas, Minnesota, and Oregon. The Minnesota MMCAP RFP (S1070000015802), posted January 20, 2026 with a March 26, 2026 response deadline, sought manufacturers for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026 and a two-year initial term. Seminole County, Florida (IFB 60459723LAS, posted June 30, 2026) sought 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly delivery to a community health building and a two-year initial term plus one-year renewal option. The City of Tampa (26P00145, posted March 25, 2026, due March 13, 2026) issued an IFB for 169 line items of medical and first aid supplies for its Fire Department Rescue Division, designated as a sheltered market for certified Small Local Business Enterprises with a 5% bid discount capped at $10,000 and an estimated contract value of $700,000. Texas HHS issued an RFI (HHS0017013, posted April 3, 2026) to explore direct-to-manufacturer prescription programs with self-insured plans and state agencies, gathering vendor capability data prior to formal RFP issuance. The code shows limited neomycin-specific procurement; vendors pursuing this code should verify alignment with broader pharmaceutical supply, emergency medical consumables, or generic drug distribution before bid preparation.